The transit effect (recognized by EFSA):
The activity of Solactis® Galactofructose beneficially affects the transit. EFSA recognized in COMMISSION REGULATION (EU) No 432/2012 of 16th May 2012 establishing a list of permitted health claims made on foods, that Solactis® Galactofructose contributes to an acceleration of intestinal transit. Solactis® Galactofructose is fermented by the colonic bacteria in short chain volatile fatty acids with two consequences. On the one hand, the osmotic gradient in the colon and consequently the water level of the colonic content is increased, which in turn increases the volume of the stools. On the other hand, the pH level of the colon drops. The increase of stool volume and colonic acidity stimulate the peristalsis and the colonic transit time is subsequently reduced. Furthermore, the higher biomass of the Bifidobacteria contributes to increasing the volume of the stools and reducing the transit time.
Conditions of use of the claim: The claim may be used only for food which contains 10g of lactulose (or galactofructose) in a single quantified portion. In order to bear the claim, information shall be given to the consumer that the beneficial effect is obtained with a single serving of 10g of lactulose (or galactofructose) per day.
The prebiotic effect (recognized by KFDA):
Solactis® Galactofructose is the major reference in prebiotic action: it’s a non-digestible food which has a beneficial impact on the intestinal flora, through selective stimulation of the growth and the activity of certain bacteria, and in particular the Bifidobacteria. The consumption of food containing Solactis® Galactofructose is subsequently associated with several health benefits, thanks to a more balanced intestinal flora.. Numerous clinical studies have demonstrated the prebiotic effect of Solactis® Galactofructose, in particular as a result of the significant increase of the number of Bifidobacteria when the product is consumed. These studies have been performed on healthy subjects, in different physiological stages. The consumption of Solactis® Galactofructose during these surveys did not have any side effects.
The Korean Food and Drug Authority recognize the prebiotic effects of Solactis® Galactofructose. The combination of these two effects of Solactis® Galactofructose, “prebiotic and transit”, contribute to better intestinal comfort and improved well-being in general.
Solactis® Galactofructose is beneficial for the mineral metabolism. Lower intestinal pH levels result in increased solubility of minerals, including calcium. A clinical survey in women also indicated improved absorption of vitamin D as a result of food supplements with Solactis® Galactofructose.
And last but not least, the effect of Solactis® Galactofructose on the metabolism of glucose and the resistance to insulin, as well as the preventive effect on type 2 diabetes are also documented.